NASDAQ:HGSI - Human Genome Sciences Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Human Genome Sciences, Inc. (HGS) is a biopharmaceutical company. The Company's products include BENLYSTA (belimumab) for systemic lupus erythematosus (SLE) and raxibacumab for inhalation anthrax. HGS continues to deliver raxibacumab to the United States Strategic National Stockpile (SNS) for emergency use in treating inhalation anthrax. In addition to the Company's internal pipeline, it has financial rights to two drugs that GlaxoSmithKline (GSK) has advanced to late-stage development. These include darapladib and albiglutide. A randomized Phase 2 trial is evaluating mapatumumab in combination with Nexavar (sorafenib) for the treatment of advanced hepatocellular cancer. The Company manufactures multiple protein and antibody drugs for use in research, clinical and commercial activities. It produces and purifies these protein and antibody drugs in three process development and manufacturing facilities. In August 2012, GlaxoSmithKline plc acquired HGS.

Receive HGSI News and Ratings via Email

Sign-up to receive the latest news and ratings for HGSI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Current SymbolNASDAQ:HGSI



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable

Human Genome Sciences (NASDAQ:HGSI) Frequently Asked Questions

What is Human Genome Sciences' stock symbol?

Human Genome Sciences trades on the NASDAQ under the ticker symbol "HGSI."

Has Human Genome Sciences been receiving favorable news coverage?

News articles about HGSI stock have trended somewhat positive on Monday, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Human Genome Sciences earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an effect on the company's share price in the next several days.

What other stocks do shareholders of Human Genome Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Human Genome Sciences investors own include Bank of America (BAC), InterMune (ITMN), Intel (INTC), Alphabet (GOOG), First Solar (FSLR), Finisar (FNSR), Dell (DELL), Changyou.Com (CYOU), Cisco Systems (CSCO) and Advanced Micro Devices (AMD).

How do I buy shares of Human Genome Sciences?

Shares of HGSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Human Genome Sciences' official website?

The official website for Human Genome Sciences is

How can I contact Human Genome Sciences?

Human Genome Sciences' mailing address is 14200 Shady Grove Rd, ROCKVILLE, MD 20850-7464, United States. The biopharmaceutical company can be reached via phone at +1-301-3098504.

MarketBeat Community Rating for Human Genome Sciences (NASDAQ HGSI)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  124 (Vote Outperform)
Underperform Votes:  137 (Vote Underperform)
Total Votes:  261
MarketBeat's community ratings are surveys of what our community members think about Human Genome Sciences and other stocks. Vote "Outperform" if you believe HGSI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HGSI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/22/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel